deltatrials
Completed PHASE2 NCT01603446

L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome

Pilot Study to Investigate the Efficacy of L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome.

Sponsor: The Hospital for Sick Children

Conditions MELAS Syndrome
Interventions L-Arginine
Updated 5 times since 2017 Last updated: Dec 13, 2013 Started: May 31, 2012 Primary completion: May 31, 2013 Completion: Dec 31, 2013

This PHASE2 trial investigates MELAS Syndrome and is currently completed. The Hospital for Sick Children leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The Hospital for Sick Children
Data source: The Hospital for Sick Children

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Toronto, Canada